Kevin Patrick Danahy - 18 Feb 2026 Form 4 Insider Report for PULSE BIOSCIENCES, INC. (PLSE)

Reporting relationship: Chief Commercial Officer
Issuer ticker: PLSE
Reported as of: 18 Feb 2026
Net transaction value: -$110,550
SEC form: 4
Accepted by SEC: 23 Feb 2026, 20:55:39 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact

Key filing fact

Kevin Patrick Danahy filed Form 4 for PULSE BIOSCIENCES, INC. (PLSE) on 23 Feb 2026.

Key facts

This page summarizes Kevin Patrick Danahy's Form 4 filing for PULSE BIOSCIENCES, INC. (PLSE).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2026, 20:55.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: -$110,550.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001913245 Primary reporting owner

Danahy Kevin Patrick

Relationship: Chief Commercial Officer
Address: C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Signature date: 23 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLSE transaction

Common Stock

Options Exercise

Transaction value: $7,650
Shares: +5,000
Change %: +12%
Price: $1.53
Shares after: 48,298
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1

PLSE transaction

Common Stock

Sale

Transaction value: $118,200
Shares: -5,000
Change %: -10%
Price: $23.64
Shares after: 43,298
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLSE transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -5,000
Change %: -1.6%
Price: $0.000000
Shares after: 300,000
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $1.53
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.

Footnote F2

The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.40 to $24.40 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

Footnote F3

Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.